|
|
Article: In New Studies Starlix(R) (Nateglinide) Enhanced Early Insulin Secretion And Controlled Mealtime Blood Glucose Levels.
- Article from:
- PR Newswire
- Article date:
- June 10, 2000
CopyrightCOPYRIGHT 2000 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN ANTONIO, June 10 /PRNewswire/ --
The following was released today by Novartis Pharmaceuticals Corporation (NYSE: NVS):
Starlix(R) (nateglinide), an investigational agent for the treatment of type 2 diabetes, enhanced early insulin release and appeared to mimic the body's normal insulin response to mealtime increases in blood glucose, according to data presented today during the American Diabetes Association's 60th Annual Scientific Sessions in San Antonio. This enhancement of early insulin release provided mealtime glucose control while reducing total insulin exposure.
"Reducing mealtime glucose spikes contributes to overall glycemic ...